Actos®, the brand name for the compound pioglitazone, is a drug used to treat Type 2 Diabetes. Actos® belongs to a class of drugs known as thiazolidinediones which operate by lowering insulin resistance in muscle and fat tissue in the body. They also reduce the amount of glucose produced by the liver. However, individuals taking Actos® are at an increased risk of developing bladder cancer. Many individuals have filed lawsuits against the manufacturer of Actos® to recover damages related to their development of bladder cancer after taking Actos®. All of the lawsuits filed in U.S. Federal Courts have been consolidated in the Western District of Louisiana in front of Judge Rebecca F. Doherty in MDL No. 2299.
When many individuals file similar lawsuits against the same entity, typically a pharmaceutical or medical device manufacturer, the United States Federal Court System can create an MDL (multidistrict litigation) where the lawsuits are consolidated for pretrial purposes. The purpose of an MDL is to streamline the discovery process so that discovery can be conducted one time and can then be used in each of the individual cases in the MDL once they are remanded back to their home districts. The Judicial Panel on Multidistrict Litigation consolidated the existing Actos® lawsuits in December 2011 into MDL 2299. Part of the MDL process once discovery is complete is to conduct “bellwether” trials to help the parties determine the value of the cases. The first bellwether trial in the Actos® MDL ended in a $9 Billion jury verdict in April 2014.
The attorneys at Franklin D. Azar and Associates are experienced in handling pharmaceutical cases from start to finish. We are here to help you if you have been wrongfully injured by a pharmaceutical drug like Actos®. Our attorneys are standing by to help you in your times of need. Call us today for a free consultation.